Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688273's EV-to-EBIT is ranked worse than 73.65% of 482
companies
in the Medical Devices & Instruments industry
Industry Median: 18.035
vs SHSE:688273: 32.62
Nanjing Medlander Medical Technology Co (SHSE:688273) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nanjing Medlander Medical Technology Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥3,216.3 Mil.
Nanjing Medlander Medical Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥72.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co EV-to-EBIT Related Terms
Nanjing Medlander Medical Technology Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co EV-to-EBIT Chart
Nanjing Medlander Medical Technology Co Annual Data
SHSE:688273 vs ABT, SYK, MDT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Medlander Medical Technology Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nanjing Medlander Medical Technology Co's EV-to-EBIT falls into.
Nanjing Medlander Medical Technology Co's current Enterprise Value is ¥2,374.9 Mil.
Nanjing Medlander Medical Technology Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥72.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Medlander Medical Technology Co (SHSE:688273) has a EV-to-EBIT of 32.62 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nanjing Medlander Medical Technology Co and its competitors. This is 105% above median its historical median of 15.92. Over the past decade, Nanjing Medlander Medical Technology Co's EV-to-EBIT has ranged from 7.57 to 47.34. According to the industry distribution chart, Nanjing Medlander Medical Technology Co ranks #355 out of 482 companies in the Medical Devices & Instruments industry, placing it in the top 73.7%.
Is Nanjing Medlander Medical Technology Co's EV-to-EBIT too high?
Nanjing Medlander Medical Technology Co's current EV-to-EBIT of 32.62 is 105% above median its 10-year median of 15.92. Over the past 10 years, this metric has ranged from a low of 7.57 to a high of 47.34. The Medical Devices & Instruments industry median EV-to-EBIT is 18.04. Nanjing Medlander Medical Technology Co's value of 32.62 is 80.9% above this industry median. Based on the distribution chart, Nanjing Medlander Medical Technology Co ranks #355 out of 482 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nanjing Medlander Medical Technology Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Medlander Medical Technology Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Medlander Medical Technology Co ranks #355 out of 482 companies for EV-to-EBIT. This places Nanjing Medlander Medical Technology Co in the lower half of its industry. The industry median EV-to-EBIT is 18.04. Nanjing Medlander Medical Technology Co's value of 32.62 is 80.9% above this benchmark. Historically, Nanjing Medlander Medical Technology Co's own EV-to-EBIT has ranged from 7.57 to 47.34 over the past decade. While the company's 10-year median is 15.92 vs. the industry median of 18.04, Nanjing Medlander Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.04, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Medlander Medical Technology Co's current EV-to-EBIT of 32.62 is 80.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nanjing Medlander Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Medlander Medical Technology Co's current EV-to-EBIT is 32.62, which is 105% above median its own 10-year median of 15.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Medlander Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co (SHSE:688273) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥35.19, compared to a current price of ¥30.41 — trading 13.6% below its estimated fair value. The current EV-to-EBIT is 32.62, which is 105% above median its 10-year median of 15.92 and 80.9% above the Medical Devices & Instruments industry median of 18.04. Nanjing Medlander Medical Technology Co's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nanjing Medlander Medical Technology Co (SHSE:688273), the current EV-to-EBIT is 32.62 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Medlander Medical Technology Co (SHSE:688273) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Medlander Medical Technology Co stock appears to be undervalued.
The current stock price of ¥30.41 is trading 13.6% below its estimated GF Value™ of ¥35.19.
GuruFocus considers Nanjing Medlander Medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688273:
EV-to-EBIT: 32.62 (105% above median its 10-year median of 15.92)
GF Value™: ¥35.19 vs. price of ¥30.41 (13.6% below fair value)
Industry Position: 80.9% above the Medical Devices & Instruments median (#355 of 482)
No single metric tells the full story. See the SHSE:688273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales, and service of related products in the field of pelvic floor and postpartum rehabilitation. Its products mainly include: biostimulation feedback instrument, color ultrasound diagnosis and evaluation system, magnetic stimulator, high-frequency evaluation electrocautery instrument, pelvic floor training instrument, portable postpartum recovery instrument, home pelvic floor rehabilitation therapy instrument, etc., which are widely used in obstetrics and gynecology, pelvic floor rehabilitation center, urology, anorectal department and other hospital departments.
81GF Score
Get the complete analysis for SHSE:688273
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688273 has been successfully added to your 
